Skip to main content

Table 2 Baseline characteristics for high-risk patients with CAP and HAP (excluding VAP) (CE population)

From: Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

  High-risk CAP
Ceftobiprole
(n = 193)
n (%)
Ceftriaxone ± linezolid
(n = 205)
n (%)
Male 115 (59.6) 123 (60.0)
Age ≥ 65 years 88 (45.6) 92 (44.9)
Sepsis 123 (63.7) 135 (65.9)
Pre-study antibiotics within 24 h 97 (50.3) 121 (59.0)
Valid pathogen at baseline 59 (30.6) 68 (33.2)
Patients with linezolid usea 19 (9.8) 30 (14.6)
  High-risk HAP (excluding VAP)
Ceftobiprole
(n = 169)
n (%)
Ceftazidime plus linezolid
(n = 138)
n (%)
Male 117 (69.2) 80 (58.0)
Age ≥ 65 years 106 (62.7) 86 (62.3)
Sepsis 122 (72.2) 109 (79.0)
APACHE score ≥ 15 67 (39.6) 59 (42.8)
Ventilation at baseline 22 (13.0) 24 (17.4)
Pre-study antibiotics within 24 h 101 (59.8) 81 (58.7)
Valid pathogen at baseline 100 (59.2) 89 (64.5)
Anti-pseudomonal antibioticsb 24 (14.2) 16 (11.6)
  1. aCAP patients suspected of MRSA infection received add-on linezolid if randomised to ceftriaxone; if randomised to ceftobiprole, they received add-on placebo instead of linezolid
  2. bEmpirical treatment with antibiotic therapy was added to the study treatment for 48 h in patients with a suspected infection due to Pseudomonas aeruginosa or for 5–7 days in patients with proven infection due to Pseudomonas aeruginosa
  3. APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, HAP hospital-acquired pneumonia, MRSA methicillin-resistant Staphylococcus aureus, VAP ventilator-associated pneumonia